CAMK2N1 and prostate carcinoma: CAMK2N1 is an endogenous inhibitor of calcium/calmodulin-dependent kinase II and has been reported as a tumor suppressor in hepatocellular carcinoma, prostate cancer, and colorectal carcinoma (Carneiro et al., 2019).